Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 103.0% in December

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 121,000 shares, a growth of 103.0% from the December 15th total of 59,600 shares. Based on an average trading volume of 153,600 shares, the short-interest ratio is currently 0.8 days. Currently, 0.5% of the shares of the stock are short sold.

Institutional Trading of Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC boosted its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,386 shares of the company’s stock after buying an additional 28,773 shares during the quarter. FMR LLC owned approximately 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Trading Up 0.2 %

NASDAQ:BOLT traded up $0.00 during mid-day trading on Thursday, hitting $0.52. 80,158 shares of the stock traded hands, compared to its average volume of 172,036. The stock has a market capitalization of $19.94 million, a price-to-earnings ratio of -0.30 and a beta of 0.96. Bolt Biotherapeutics has a 52 week low of $0.48 and a 52 week high of $1.56. The firm’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.64. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.02 million. On average, equities research analysts predict that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, Bolt Biotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.